Fruquintinib Capsules 1?mg ×?21 -Elunate
$1.00
Fruquintinib Capsules (brand: Elunate®) are potent, highly selective small-molecule inhibitors targeting VEGFR?1, VEGFR?2, and VEGFR?3. These capsules are used in preclinical oncology research—especially in studies of angiogenesis and colorectal cancer models. Each box contains 21 capsules of 1?mg each. Manufactured by Hutchison MediPharma (QC sub-licensee: Hutchison Pa—Indicated by code), produced by Hutchison-Med, and approved by China NMPA in 2018 under H20180015, product code 86910171000016
?? For laboratory research use only.?Please consult the staff for other purposes?
描述
Product Specifications
| Attribute | Details |
|---|---|
| Product Name | Fruquintinib Capsules (Elunate®) |
| Generic Name | Fruquintinib (HMPL?013) |
| Dosage Form | Oral capsule |
| Strength | 1?mg per capsule |
| Pack Size | 21 capsules per box |
| Approval Number | H20180015 (China NMPA) |
| Product Code | 86910171000016 |
| Manufacturer | Hutchison-owned Qilu (Suzhou) |
| Barcode | N/A |
| CAS Number | 1194506?26?7 :contentReference[oaicite:5]{index=5} |
| Molecular Formula | C??H??N?O? :contentReference[oaicite:6]{index=6} |
| Molecular Weight | ~393.4?g/mol :contentReference[oaicite:7]{index=7} |
| Storage | Store at room temperature, protect from moisture |
| Intended Use | Laboratory research only |
Mechanism of Action
Fruquintinib is a highly selective inhibitor of VEGF receptors 1, 2, and 3, blocking angiogenesis and tumor vascularization pathways in preclinical models of colorectal and other solid tumors hemonc.org+12pmc.ncbi.nlm.nih.gov+12en.wikipedia.org+12.
Research Applications & Pharmacology
-
Angiogenesis studies: Matrigel plug and tumor xenograft inhibition
-
Colorectal cancer research: Validated through Phase III FRESCO trial for mCRC adisinsight.springer.com+15pmc.ncbi.nlm.nih.gov+15en.wikipedia.org+15
-
Combination therapy: Often evaluated with chemotherapy agents in preclinical settings
-
Pharmacokinetics: Molecular weight ~393?g/mol; low aqueous solubility at pH 6.8, increases under acidic conditions
Safety Profile & Side Effects
Clinical data report common adverse effects including hypertension, hand–foot syndrome, proteinuria, and hepatotoxicity. Preclinical observations often mirror these findings. In lab environments, use PPE and monitor blood pressure and liver enzymes during animal studies .
?? Research?Use Disclaimer
This product is intended exclusively for laboratory research use. It is not approved for therapeutic, diagnostic, clinical, or veterinary applications. Misuse may pose safety risks or compromise data validity.
其他信息
| 重量 | 1.1 公斤 |
|---|---|
| 尺寸 | 18 × 16 × 18 厘米 |
相关产品
-
Letrozole Capsules (Qipuyi®) – 2.5?mg?wholesale Price comparison
Letrozole is a potent nonsteroidal aromatase inhibitor, produced by Qilu Pharmaceutical Co., Ltd. (Qipuyi® brand). Each box contains 30 capsules (2.5?mg each), packaged as 3 blister cards. It’s approved in China under NMPA No.?H20213680, code 86981659000019, with barcodes 6915798005257 and 6915798005721. Strictly for laboratory research use—not for clinical or human applications. $1.00 -
Fulzerasib Tablets (Dupert®) – 150?mg × 112 Tablets per Box Price comparison
Fulzerasib (Dupert®) is an orally active KRAS G12C inhibitor, conditionally approved in China for advanced non–small-cell lung cancer (NSCLC) with KRAS G12C mutation. Manufactured by CindaBio, NMPA approved under H20240035 (drug code: 86985200000015). Strictly for laboratory research use only—NOT for clinical or human consumption. $1.00 -
Elranatamab Injection 76?mg/1.9?mL/Freeze-dried powder
Elranatamab (ELREXFIO®) is a BCMA-CD3 bispecific antibody used in multiple myeloma research. Supplied as a 76?mg/1.9?mL single-dose vial, manufactured by Pfizer. Approved by FDA (Aug?2023) and EMA (Dec?2023). Ideal for oncology, immunotherapy, and T?cell engager studies.
$1.00
?? For laboratory research use only – Not for human consumption or therapeutic use. -
Irinotecan Hydrochloride Liposome Injection (Du’EnYi®) – 10?mL:43?mg Vial
Irinotecan Hydrochloride Liposome Injection Du’EnYi® is China’s first domestically approved liposome-encapsulated irinotecan injection, equivalent to ONIVYDE®. Each 10?mL vial contains 43?mg irinotecan and is strictly for laboratory research use only—not for clinical or human application.?Please consult the staff for other purposes? $1.00
评价
目前还没有评价